It will also be tested in patients with relapsed or refractory multiple myeloma in combination with dexamethasone and CC-92,480 (BMS-986,348) – an agent that promotes the degradation of the transcription factors Ikaros and Aiolos, which leads to apoptosis and immunomodulatory effects [158, 159] (NCT05372354). This evidence concerns the gene IKZF1 and plasma cell myeloma.